Checkmate Therapeutics is a biotech company developing differentiated immuno-oncology and oncology therapeutics.

Our lead program, CX003, is a first-in-class WNK3-selective inhibitor that suppresses tumor PD-L1, boosts CD4⁺/CD8⁺ T-cell activation, and delivers strong in vivo synergy with anti–PD-L1/VEGFA therapy in HCC.

Our second program, CX001A, is a novel NAMPT-targeting payload for next-generation ADCs, demonstrating potent mechanistic synergy with TOP1 inhibitors and target-dependent cytotoxicity in HER2-expressing models.